StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

Form 8-K Table 3 / 10-K / 10-Q MD&A

Latest, FY2025
7.0%
Period ended Dec 31, 2025
Change on a year earlier
-15.0 pts
22.0% in FY2024
History
8 years
Since FY2017
Sources
8
Documents cited below

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKeytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 20257.0%-15.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 202422.0%+1.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2023Dec 31, 202321.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 202118.0%-12.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2020Dec 31, 202030.0%-28.0 ptsForm 8-K (tm213179d2_ex99-1.htm, filed 2021-02-04) ↗
FY2019Dec 31, 201958.0%-30.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 201888.0%-83.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 2017171.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Keytruda (pembrolizumab — PD-1 immuno-oncology franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_keytruda_ww_exfx_yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.